Analysis of Celltrion's corporate history, corporate relationships, biosimilars development pipeline, and Datamonitor's evaluation of the company's strategy and key strengths, weaknesses, opportunities and threats.
Description
INTRODUCTION
This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.
FEATURES AND BENEFITS
Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.
Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.
HIGHLIGHTS
The company is thought to be responsible for filing the first biosimilar MAb for approval in Europe. In 2009, Celltrion signed an agreement to manufacture and co-market eight biosimilars with Hospira in the US, EU and other key markets. Hospira is a leader in injectable generics, representing a strong fit with biosimilars.
YOUR KEY QUESTIONS ANSWERED
Evaluate key products in Celltrion's biosimilar pipeline of seven monoclonal antibodies and one fusion protein
With no sales capabilities and a limited international footprint, see how Celltrion is reliant upon partnerships for market access and sales
Table of Contents
Table of Contents
ABOUT THIS REPORT
Chapter structure
Executive summary
Strategic insight
Product analysis
Operating performance
Corporate structure
Data sourcing
Sales data
PharmaVitae Explorer database
EXECUTIVE SUMMARY
Celltrion biosimilars summary
Celltrion biosimilars SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Celltrion biosimilars infrastructure
STRATEGIC INSIGHT
Celltrion to tap into monoclonal antibody market
Celltrion to utilize marketing alliances
KEY PRODUCTS
Overview
Celltrion's biosimilar portfolio
CT-P13 (infliximab)
Overview
Infliximab market size
Key competitors
Celltrion biosimilar development
CT-P6 (trastuzumab)
Overview
Trastuzumab market size
Key competitors
Celltrion biosimilar development
CT-P10 (rituximab)
Overview
Rituximab market sizing
Key competitors
Celltrion biosimilar development
CT-P05 (etanercept)
Overview
Etanercept market sizing
Key competitors
CT-P15 (cetuximab)
Overview
Cetuximab market sizing
Key competitors
Other biosimilars in development
CORPORATE STRUCTURE
Background
Key corporate developments and M&A history
Company structure
The Celltrion Inc. and Celltrion Healthcare relationship
Deals and alliances
Recent developments
APPENDIX
References
Websites
Datamonitor reports
Exchange rates
TABLES
Table: Celltrion - manufacturing and development metrics
Table: Celltrion - biosimilar portfolio
Table: Forecasted global Remicade sales, by region, ($m), 2011-16
Figure: MAb sales that Celltrion is targeting, 2011-16
Figure: Celltrion geographical deal coverage
Figure: Celltrion company structure
Celltrion: Biosimilars Company Analysis published by Datamonitor in July 6, 2012. This report consists of Pages: 39 and the price starts from US $ 3800.
